Neogen (NASDAQ:NEOG – Get Free Report) announced its quarterly earnings data on Friday. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.12, Briefing.com reports. The firm had revenue of $231.30 million during the quarter, compared to analyst estimates of $227.16 million. Neogen had a positive return on equity of 2.80% and a negative net margin of 2.58%. The company’s revenue was up .7% on a year-over-year basis. During the same period last year, the company earned $0.11 earnings per share. Neogen updated its FY 2025 guidance to EPS.
Neogen Stock Performance
NASDAQ NEOG opened at $13.07 on Friday. The firm has a market capitalization of $2.83 billion, a P/E ratio of -118.82 and a beta of 1.23. The company has a current ratio of 4.41, a quick ratio of 2.79 and a debt-to-equity ratio of 0.28. The firm’s fifty day moving average price is $13.54 and its two-hundred day moving average price is $15.11. Neogen has a 1 year low of $11.46 and a 1 year high of $18.75.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on the company. StockNews.com raised Neogen to a “sell” rating in a research note on Monday, September 30th. Guggenheim began coverage on shares of Neogen in a research report on Thursday, December 19th. They issued a “buy” rating and a $15.00 price target on the stock.
Neogen Company Profile
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.
See Also
- Five stocks we like better than Neogen
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3 EV Stocks Offering Unique Alternatives to Tesla
- What is a Special Dividend?
- 3 Stocks Leveraging NVIDIA’s Strength for Profits
- What is the Dow Jones Industrial Average (DJIA)?
- Walgreens Stock Poised for a Rebound: Why Analysts Are Bullish
Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.